Health and Medtech companies have always been important, but in 2020 they became one of the most focused segments. This year, Medtech’s start-ups will be spotlighted as they recover from the COVID-19 pandemic. UK-based health tech startup Huma is in the limelight for securing a remarkable £ 91.88 million in its latest funding round.
Bigwigs Funds Huma
Current funding round Huma It was led by several well-known companies. Bayer’s Leap and Hitachi Ventures led the company’s Series C funding round. Samsung Next, IGV’s Sony Innovation Fund, Unilieber Ventures, HAT Technology & Innovation Fund, and individuals Nikesh Arora (former President of Softbank) and Michael Deekman (Chairman of Allianz) also invested in the company to become new shareholders did.
Goldman Sachs International acted as Huma’s lead placement agent, HSBC Bank pl and Nomura acted as co-placement agents, and the latter became a new shareholder of the company. There is also an additional £ 49.47 million available later as part of the Series C funding round, bringing the total funding to over £ 140m.
Talking to startup CEO and founder UKTN, Dan Vahdat sheds more light on how the money is used. “Huma uses new funding primarily for growth and R & D. We want to continue developing and improving our“ home hospital ”and DCT technology to expand our biomarker library. Ultimately, we plan to expand into new regions to reach our ultimate goal of affecting as many people as possible on the planet, “he said.
Enables preventative and predictive health
Huma is a healthcare technology startup aiming to transform healthcare and research globally. Its digital “home hospital” and decentralized clinical trial platform enable patients, clinicians, researchers, and healthcare systems to stay up-to-date and up-to-date. To do this, we use real-time health data from our smartphones.
Vahdat said: “By providing people with a way to collect and share real-time real-world data via smartphones, they bring hospitals and laboratories home. Clinicians can take heart rate, oxygen levels, movements, symptoms, and more. Prescribe the app to patients who can share measurements. ”
Vahdat further explains that through Huma, clinicians have access to the dashboard of all patients. With this dashboard, you can flag your concerns, perform video hangouts to find out more, change your patient’s medications, and take your patients to the test if needed. I will. The same system is used for participants to participate in clinical trials.
Digital biomarkers for better care and research
Huma utilizes what are called digital phenotyping and digital biomarkers and is widely used to enable services. Learn more from Vahdat about what these biomarkers are. “Digital biomarkers are digital measurements or combinations of digital measurements captured via smartphones, wearables, or other sensors,” he explains.
These digital measurements can be used to provide valuable insights into specific health outcomes and to provide information about the risks or susceptibility of specific conditions. It can also provide diagnostic or prognostic information to patients and clinicians.
During the COVID pandemic, the company focused its efforts to help care for Covid-19 patients at home. Vahdat adds: “The NHSX reports that clinical capacity has almost doubled and readmission rates have dropped by a third. Using the same system, we are currently supporting hospitals on the waiting list. We have already flagged about 10% of patients for exacerbations, and as a result, surgery is underway in one-third. “
Huma also collects important data through the platform, which also enables better research opportunities. You can participate in clinical trials on your smartphone, reducing the need to go to a clinic or hospital. This is said to result in faster recruitment, faster data collection, and a wider variety of participants for better data.
“In the UK, only 56% of trials employ the desired number of patients. According to 2015 data, 20% worldwide failed altogether, but in 2020, in the United States, with Stanford University School of Medicine. Bayer expects to take nine months to recruit patients and helped do that in a month, “Vahdat adds.
Founded in 2011 by Dan Vahdat and Rich Khatib, Huma has been on an interesting journey. We currently employ 150 people and are actively hiring new talent around the world. When it comes to the future of digital therapy, Vahdat believes it will be exciting.
“There is a great deal of interest in digital biomarkers and therapies for teams around the world to detect, predict and treat illnesses and receive the type of care that is usually limited to very wealthy people. There are many digital biomarkers under development that will soon be clinically validated and widely used, ”Vahdat concludes.
UK “hospital home” startup Huma raises $ 130 million from Bayer and Hitachi
Source link UK “hospital home” startup Huma raises $ 130 million from Bayer and Hitachi